Trump invoked Section 232, the national security trade authority, to slap 100% tariffs on imported pharmaceuticals Thursday. The announcement looked like a body blow to Big Pharma. Then came the exemptions.
Thirteen drugmakers that pledged a collective $400 billion in U.S. manufacturing investment, and agreed to most-favored-nation pricing deals, won’t face the full rate. Generics and biosimilars aren’t touched at all, though the administration said it will reassess that decision in a year. Drugs from the EU, Japan, Korea, Switzerland, and Liechtenstein face a softer 15% levy — and the UK gets its own separate rate the White House didn’t specify. Orphan and specialty drugs get a pass if they’re from a trade deal country or meet an “urgent public health need.”
Who’s exposed? Mid-sized biotechs pursuing large indications that didn’t cut deals and don’t benefit from generic carve-outs. The Mid-Sized Biotech Alliance of America is already lobbying hard for reversal. PhRMA is opposing the policy, and its president called tariffs an obstacle to “affordable, lifesaving medicines.” PhRMA has not ruled out litigation to block implementation.
The deeper structural problem is the sunset date. Every exemption expires January 20, 2029. Companies are making 20-year capital decisions against three years of policy certainty. RBC analyst Trung Huynh called it “a positive relative to investor sentiment.” He flagged one risk: if the next administration reverses course, “$400 billion becomes stranded cost.”
Large company tariffs kick in within 120 days. Smaller companies get 180.
James Okafor